USO 20283
A Phase 2 Study Of Brentuximab Vedotin In Combination With Pembrolizumab In Subjects With Metastatic Solid Malignancies After Progression On Prior PD-1 Inhibitor Treatment (SGN35-033)
Disease Types: Solid Tumors Research
Eligibility Requirements:
-relapsed/refractory metastatic squamous or non-squamous metastatic NSCLC (EGFR, ALK, ROS 1, & BRAF negative) or metastatic cutaneous melanoma with measurable disease
-Must be currently on PD-1 checkpoint inhibitor therapy or must be last previous line of therapy, must have progressed on anti-PD-1 monotherapy or combination therapy
-No: known active CNS metastasis or carcinomatous meningitis; history of progressive multifocal leukoencephalopathy; known Hep B or Hep C (treated allowed); previous treatment with brentuximab vedotin; pulmonary disease unrelated to NSCLC or melanoma; history of stroke, TIA, unstable angina, MI, congestive
heart failure class 3 or 4 within last 6 months; neuropathy grade 2+; active autoimmune disease or immunodeficiency requiring systemic immunosuppressive therapy; pneumonitis or idiopathic interstitial pneumonia; allogenic tissue or solid organ transplant; grade 3+ immune related adverse events due to
therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, CTLA-4, OX 40, CD137 treatment
Available at: